Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Neutrophil-To-Lymphocyte Ratio As a New Prognostic Factor in Cancers: A Narrative Review Publisher



Heshmatghahdarijani K1 ; Sarmadi V2 ; Heidari A2 ; Falahati Marvasti A3 ; Neshat S2, 4 ; Raeisi S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cardiac Rehabilitation, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  4. 4. Department of Biostatistics and Epidemiology, University of California, San Francisco, San Francisco, CA, United States

Source: Frontiers in Oncology Published:2023


Abstract

The increasing incidence of cancer globally has highlighted the significance of early diagnosis and improvement of treatment strategies. In the 19th century, a connection was made between inflammation and cancer, with inflammation recognized as a malignancy hallmark. The neutrophil-to-lymphocyte ratio (NLR), calculated from a complete blood count, is a simple and accessible biomarker of inflammation status. NLR has also been proven to be a prognostic factor for various medical conditions, including mortality classification in cardiac patients, infectious diseases, postoperative complications, and inflammatory states. In this narrative review, we aim to assess the prognostic potential of NLR in cancer. We will review recent studies that have evaluated the association between NLR and various malignancies. The results of this review will help to further understand the role of NLR in cancer prognosis and inform future research directions. With the increasing incidence of cancer, it is important to identify reliable and accessible prognostic markers to improve patient outcomes. The study of NLR in cancer may provide valuable insights into the development and progression of cancer and inform clinical decision-making. Copyright © 2023 Heshmat-Ghahdarijani, Sarmadi, Heidari, Falahati Marvasti, Neshat and Raeisi.
Other Related Docs
14. The Prominent Role of Mir-942 in Carcinogenesis of Tumors, Advanced Biomedical Research (2022)
24. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
42. The Needs of Colorectal Cancer Patients/Survivors: A Narrative Review, Journal of Education and Health Promotion (2022)